ACADEMIA

Whistle-Blower Insists There Were Willful Data Falsifications in J-ADNI Project

July 9, 2014
A whistle-blower for data-tampering suspicion in a large-scale Alzheimer’s disease project barked at investigation findings of the University of Tokyo, which dismissed the allegation by concluding that the data changes found were merely “inappropriate corrections.” At a press conference on…

To read the full story

Related Article

ACADEMIA

By Sakura Kono

Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not…

A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

By Philip Carrigan

In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…

By Ken Yoshino

The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…